熱門資訊> 正文
雅培推出非处方血糖监测仪Lingo
2024-09-05 23:37
- Abbott Laboratories (NYSE:ABT) on Thursday announced the market launch of Lingo, its first continuous glucose monitoring system available without a prescription.
- The North Chicago, Illinois-based MedTech giant said that Lingo is available for people aged 18 and above who are not on insulin.
- Abbott (ABT) and its rival in the glucose monitoring space, DexCom (DXCM), won FDA clearances for their over-the-counter CGM devices in June ahead of their planned market rollouts this summer.
- Last week, DexCom (DXCM) launched its product, Stelo, at $99 for a single pack of two sensors. Abbott (ABT) has priced its device at $89 for two sensors.
- "Abbott's Lingo tracks your glucose 24/7, translating the data into insights and bridging the gap between traditional healthcare and preventative measures," said Olivier Ropars, Abbott's divisional vice president of Lingo.
More on Abbott Laboratories
- Abbott Laboratories: A Dividend Aristocrat To Buy Now
- Abbott Laboratories: Driving Value By Scaling Innovations
- Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors
- UNICEF issues emergency tender to secure mpox vaccines
- U.S. to restart free COVID test program as cases spike
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
